Get the Stockscreener App
50.71
2.56%
-1.33
After Hours:
50.71
Guardant Health Inc stock is traded at $50.71, with a volume of 1.74M.
It is down -2.56% in the last 24 hours and up +24.84% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$52.04
Open:
$51.72
24h Volume:
1.74M
Relative Volume:
0.83
Market Cap:
$6.07B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-11.96
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+1.44%
1M Performance:
+24.84%
6M Performance:
+65.99%
1Y Performance:
+79.44%
1-Day Range:
$50.05
$51.96
1-Week Range:
$48.07
$53.42
52-Week Range:
$20.14
$53.42
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
50.71 | 6.07B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
421.47 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
201.10 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.65 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.45 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing
Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine
Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director sells shares worth $157,573 - Investing.com
Guardant Health Executives Sell Shares - TradingView
Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Guardant Health (NASDAQ:GH) Given New $65.00 Price Target at Mizuho - MarketBeat
(GH) Investment Report - news.stocktradersdaily.com
Mizuho raises Guardant Health price target on positive Shield test outlook - Investing.com Canada
Guardant Health (GH) Price Target Raised to $65 by Mizuho | GH S - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Guardant Health, Inc. (NASDAQ:GH) Receives $53.29 Consensus PT from Analysts - MarketBeat
Guardant Health Wins Fast Company's 2025 World Changing Ideas Aw - GuruFocus
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening | GH Stock News - GuruFocus
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening - Yahoo Finance
Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility - The ASCO Post
Insider Sell: Amirali Talasaz Sells 119,284 Shares of Guardant H - GuruFocus
Guardant Health Inc (GH) Shares Up 4.04% on Jun 9 - GuruFocus
Guardant Health at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Transcript : Guardant Health, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - BioSpace
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer | GH Stock News - GuruFocus
ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | G - GuruFocus
Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN
Insider Sell: Kumud Kalia Sells 4,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health Inc (GH) Shares Up 3.5% on Jun 5 - GuruFocus
Mackenzie Financial Corp Has $230,000 Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Guardant Health Shares Climb on FDA Breakthrough Status for Cancer Detection Test - MSN
Minimal Residual Disease Testing Market Set to Witness - openPR.com
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | GH Stock News - GuruFocus
Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia
Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant By Investing.com - Investing.com UK
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN
Guardant Health gets FDA breakthrough device status for cancer detection test - MSN
Guardant Health’s MCD test earns FDA breakthrough designation - Yahoo
111 Capital Purchases Shares of 8,303 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health’s cancer test earns FDA breakthrough status By Investing.com - Investing.com South Africa
Leerink Partners maintains outperform rating for Guardant Health stock By Investing.com - Investing.com Canada
ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus
Guardant Health (GH) Stock Surges on FDA Breakthrough Designatio - GuruFocus
Why Guardant Health Stock Surged Nearly 9% Higher Today - MSN
NCCN Adds 2 Tests to CRC Screening Guidelines - OncLive
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?Guardant Health (NASDAQ:GH) - Benzinga
Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa
Guardant Health shares rise following FDA breakthrough designation - Investing.com
Guardant Health (GH) Gains as FDA Grants Breakthrough Designatio - GuruFocus
Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com
Guardant Health’s cancer test earns FDA breakthrough status - Investing.com
Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| POTTER MYRTLE S | Director |
Jun 18 '25 |
Sale |
49.47 |
26 |
1,286 |
18,154 |
| CLARK IAN T | Director |
Jun 17 '25 |
Sale |
48.38 |
6,672 |
322,819 |
9,851 |
0.17%
2.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):